Romania Child Vaccinations: Schedule & Information

2025 Vaccination Schedules: Protecting Children and Boosting Public Health in Europe

The European Union is prioritizing robust vaccination programs to safeguard public health, with updated schedules set to take effect in 2025. These initiatives, overseen by the European Medicines Agency and implemented by individual member states, aim to ensure safe and effective immunization against a range of potentially life-threatening diseases. A recent surge in misinformation and disruptions to healthcare access have underscored the critical importance of maintaining high vaccination rates across the continent.

The Role of European Agencies in Vaccine Safety and Approval

The European Medicines Agency (EMA) is the central authority responsible for evaluating and monitoring the safety of vaccines before they can be administered. Following rigorous testing, the European Commission then issues authorization for vaccines to be introduced to the market. While the EMA provides a unified standard, vaccination schedules themselves can vary between countries, reflecting differences in local epidemiology and healthcare priorities. These variations encompass the age of administration, targeted population groups, dosage schedules, and the possibility of administering multiple vaccines simultaneously.

National Vaccination Calendar for 2025: A Timeline of Protection

According to the National Vaccination Calendar valid in 2025, a comprehensive immunization schedule is recommended for all children. Key vaccines and their corresponding administration timelines include:

• Hepatitis B: Administered within the first 24 hours of life in the maternity ward.
• BCG (Calmette-Guerrin): Given between days 2-7 of a newborn’s life, offering protection against tuberculosis.
• DTPa-VPI-Hib-Hep.B & Antipneumococcal: Administered at 2, 4, and 11 months of age by a family doctor, providing immunization against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, Haemophilus influenzae type B, pneumonia, and acute otitis media.
• MMR (Measles, Rubella, Mumps): Administered at 1 and 5 years of age by a family doctor.
• DTPa-VPI: Given between 5-6 years of age by a family doctor.
• DTP: Administered at 14 years of age at the family doctor’s office.

Understanding Vaccine-Specific Eligibility and Contraindications

Each vaccine has specific criteria for administration and potential contraindications.

Hepatitis B vaccine protects against infection caused by the hepatitis B virus and associated complications like liver fibrosis and cancer. Immunization is achieved through a vaccine containing the virus’s major surface antigen. Contraindications include severe allergic reactions and hypersensitivity to components like yeast or egg proteins.

The Calmette-Guerrin BCG vaccine remains the sole vaccine offering protection against tuberculosis, leprosy, and Buruli ulcer. Immunosuppression, whether congenital or secondary (such as HIV infection or corticosteroid use), is a key contraindication.

The combined DTPa-VPI-Hib-Hep.B and anti-pneumococcal vaccine provides broad protection against several serious diseases. However, the pneumococcal conjugate vaccine does not replace the 23-valent polysaccharide vaccine for children over 2 years with underlying conditions like sickle cell anemia or HIV, who are at increased risk. Contraindications include severe reactions to vaccine components, neomycin, or polymyxin. Special consideration is needed for premature infants (≤ 28 weeks gestation) with respiratory immaturity, requiring 48-72 hours of respiratory monitoring post-vaccination.

The MMR vaccine can be administered alongside inactivated vaccines like influenza or COVID-19, or one month before or after live virus vaccines like varicella. Contraindications include anaphylactic reactions to the vaccine or its components, or severe immunodeficiency.

The DTPa-VPI vaccine protects against diphtheria, tetanus, whooping cough, and poliomyelitis and can be given alone or with other biological preparations. Contraindications include hypersensitivity to vaccine components or a history of severe reactions or encephalopathy following a previous dose.

Beyond the Basics: Optional Vaccines for Enhanced Protection

Parents have the option to further protect their children with additional vaccines, including:

• Rotavirus vaccine: Administered orally at 2 and 3 months to prevent rotavirus infection, which can cause severe dehydration.
• Antimeningococcal vaccine: Given at 2 and 4 months, with a booster after one year, to protect against meningococcal meningitis.
• Influenza vaccine: Recommended before the winter season, available in inactivated, live attenuated, quadrivalent, and trivalent forms.
• HPV vaccine: Currently available in Romania for individuals aged 19-45 with partial compensation, and included in the National Immunization Plan for both girls and boys aged 11-18.
• Varicella vaccine: Administered from 12 months of age, or under specific conditions from 9 months, but contraindicated for individuals with oncological conditions, HIV, or those on immunosuppressants.
• Hepatitis A vaccine: Recommended for children and adolescents aged 1-15 in two doses, 6-12 months apart.

Addressing Declining Vaccination Rates and Building Confidence

Recent declines in vaccination rates across the European Union are attributed to factors including limited access for disadvantaged communities, supply disruptions, misinformation, and geopolitical instability. The coronavirus pandemic significantly eroded public trust in vaccines, fueled by the spread of false and misleading information.

To combat this trend, the European Commission actively supports member states in maintaining and increasing vaccination rates. The “United Protection” communication campaign, launched between 2022-2025, aims to raise public awareness about the benefits of vaccination at all stages of life.

Maintaining high vaccination coverage remains a critical public health priority, requiring continued efforts to address misinformation, improve access, and build confidence in the safety and efficacy of vaccines.